

This is a repository copy of *Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/152176/>

Version: Accepted Version

---

**Article:**

Walker, Ian F., Shi, Oumin, Hicks, Joseph P. et al. (13 more authors) (2019) Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. *European Respiratory Journal*. 1800353. ISSN 1399-3003

<https://doi.org/10.1183/13993003.00353-2018>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



## Analysis of loss to follow up in 5,970 multidrug-resistant pulmonary tuberculosis patients

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Walker, Ian; University of Leeds, Nuffield Centre for International Health and Development</p> <p>Shi, Oumin; University of Toronto Dalla Lana School of Public Health; Shenzhen Second People's Hospital</p> <p>Hicks, Joseph; University of Leeds, Nuffield Centre for International Health and Development</p> <p>Elsey, Helen; University of Leeds, Nuffield Centre for International Health and Development</p> <p>Wei, Xiaolin; University of Toronto Dalla Lana School of Public Health, Menzies, Dick; Montreal Chest Institute, Respiratory Epidemiology and Clinical Research Unit</p> <p>Falzon, Dennis; WHO, STB-TBC</p> <p>Migliori, Giovanni Battista; S. Maugeri Foundation, Who Collaborating Centre for TB;</p> <p>Pérez-Guzmán, Carlos; Instituto Mexicano del Seguro Social, Vargas, Mario; Instituto Nacional de Enfermedades Respiratorias, Unidad de Investigación</p> <p>García-García, Lourdes; Instituto Nacional de Salud Pública, Centro de Investigación sobre Enfermedades Infecciosas</p> <p>Sifuentes-Osornio, José; (4) Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán", Department of Medicine</p> <p>Ponce-de-Leon, Alfredo; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán", Infectología</p> <p>van der Walt, Martha; South African Medical Research Council</p> <p>Newell, James; University of Leeds, Nuffield Centre for International Health and Development</p>
Key Words:	Tuberculosis (TB), drug resistance, adherence to therapy, epidemiology, pulmonary tuberculosis

**Analysis of loss to follow up in 5,970 multidrug-resistant pulmonary tuberculosis patients**

Ian F. Walker<sup>1</sup>, Oumin Shi<sup>2,3</sup>, Joseph Hicks<sup>1</sup>, Helen Elsey<sup>1</sup>, Xiaolin Wei<sup>2</sup>, Dick Menzies<sup>4</sup>, Dennis Falzon<sup>5</sup>, Giovanni Battista Migliori<sup>6</sup>, Carlos Pérez-Guzmán<sup>7,8</sup>, Mario H. Vargas<sup>8,9</sup>, Lourdes García-García<sup>10</sup>, José Sifuentes Osornio<sup>11</sup>, Alfredo Ponce-De-León<sup>12</sup>, Martie van der Walt<sup>13</sup> and James N. Newell<sup>1</sup>

- <sup>1</sup>Nuffield Centre for International Health and Development, University of Leeds, UK
- <sup>2</sup>Dalla Lana School of Public Health, University of Toronto, Canada
- <sup>3</sup>Shenzhen Second People's Hospital, Shenzhen University, Shenzhen, Guangdong, China
- <sup>4</sup>Montreal Chest Institute, McGill International TB Centre, McGill University, Canada
- <sup>5</sup>Global TB Programme, World Health Organization, Switzerland
- <sup>6</sup>World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico, Tradate, Italy
- <sup>7</sup>Hospital General Tercer Milenio, Aguascalientes, Aguascalientes, Mexico
- <sup>8</sup>Mexican Institute of Social Security (Instituto Mexicano del Seguro Social), Mexico
- <sup>9</sup>National Institute of Respiratory Diseases (Instituto Nacional de Enfermedades Respiratorias), Mexico
- <sup>10</sup>Center for Research on Infectious Diseases (Instituto Nacional de Salud Pública), Mexico
- <sup>11</sup>Dirección de Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- <sup>12</sup>Laboratorio Nacional de Maxima Seguridad Biológica y Microbiología Clínica, departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- <sup>13</sup>South African Medical Research Council, South Africa

Corresponding Author: Ian Walker, Rm 1031, Worsley Building, University of Leeds, Clarendon Way, Leeds, LS2 9NL. Tel: +44 (0)113 343 0878. Email: [i.walker@leeds.ac.uk](mailto:i.walker@leeds.ac.uk)

Take home message: Loss to follow up risk is constant throughout MDRTB treatment globally. ↑risk = men, HIV+, 26-50yrs & standard regime

**Abstract**

Loss-to-follow-up (LFU) of two or more consecutive months contributes to the poor levels of treatment success in multidrug-resistant tuberculosis (MDR-TB), reported by TB programmes. We explore the timing when LFU occurs by month of MDR-TB treatment and identify patient-level risk factors associated with LFU.

We analysed a dataset of individual MDR-TB patient data (5,970 patients from 23 countries). We used Kaplan-Meier survival curves to plot time to LFU and a Cox proportional hazards model to explore the association of potential risk factors with LFU.

One-fifth (n=1,282) of patients were recorded as LFU. Median time to LFU was 16 months (IQR=6-18). A sharp increase in rate of LFU at month 18 of treatment was identified as artefactual from one large cohort. Risk factors associated with LFU were age (26-35yrs: Hazard Ratio (HR) 1.20; 95% CI 1.04, 1.39 and 36-50yrs: HR 1.28; 95% CI 1.09, 1.49 compared with age 0-25yrs), being male (HR 1.13; 95% CI 1.04, 1.23), HIV positive (HR 1.36; 95% CI 1.02, 1.80) and treatment with a standardised regimen (individualised treatment had HR 0.55; 95% CI 0.32, 0.93 compared with standardised regimen).

Both patient and regimen-related factors were associated with LFU which may guide interventions to improve treatment adherence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Introduction**

Multidrug-resistant tuberculosis (MDR-TB) is a growing challenge to TB treatment programmes globally. Treatment completion rates remain low at 50% with 16% lost to follow up (LFU - previously termed “treatment default”)[1-4] – defined as MDR-TB patients “whose treatment was interrupted for two consecutive months or more”. [5] Patients who do not complete pulmonary MDR-TB treatment pose a public health risk of ongoing transmission of resistant, infectious disease as well as a high likelihood of death for the patient.

Current evidence from MDR-TB treatment cohorts, identifies that LFU is associated with being male,[6] substance misuse,[6-11] resistance to a high number of anti-TB drugs, [6, 12, 13] the absence of early culture conversion,[6, 11, 13, 14] poor patient-provider relationships,[8, 10] greater disease severity,[7] HIV co-infection[15] and the occurrence of drug side effects.[10, 13]

Several studies suggest that the majority of LFU takes place in the early stages of MDR-TB treatment when patients may still be infectious. The percentage of total LFU that occurred in the intensive phase (first 6-8 months) of MDR-TB treatment was 77.8% in the Philippines (total sample size(N)=273, total LFU=91)),[10] 71.1% in Armenia (N=381, LFU=97),[13] 72.7% in Pakistan (N=186, LFU=33)[16] and 40.8% in Georgia (N=1,240, LFU=458).[11] The total LFU occurring by six months was 86.9% in India (N=796, LFU=153).[14] In Uzbekistan, median time to LFU was 6 months (N=710, LFU=142).[12]

Several strategies have been attempted by TB programmes to reduce LFU[17], including providing directly observed treatment (DOT) throughout the course of treatment,[18] providing patient education and managing smaller numbers of patients.

To optimise the management of MDR-TB patients, national TB treatment programmes would benefit from knowing who are at risk of LFU and when it is likely to occur. Interventions targeted at individuals with these risk factors and these time points could reduce rates of LFU and ultimately assist in controlling the epidemic. Analysis to specify the time of LFU more accurately would optimise the timing of such interventions. Here we are able to use the largest ever multi-country, individual

MDR-TB dataset, to identify the timing of LFU in the treatment of pulmonary MDR-TB and to identify patient-level risk factors associated with LFU. [1-3]

## Methods

The dataset of the *Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB* was used for this analysis. This data set includes individual-level treatment data from 9,153 pulmonary MDR-TB patients from TB clinics or programmes from 23 countries, reported in 32 previously published observational studies. Patients had to have received at least one month's treatment in order to be included. The patient characteristics and definitions of the variables within the dataset have been described elsewhere.[1] Permission was not granted for this analysis, for one cohort of patients included in the original data set.

For our analysis, patients were included if there was authorization of the lead investigator for each cohort and patients were alive at the point of LFU. Patients were defined as LFU if their outcome was recorded as 'defaulted', 'transferred out (with unknown outcome)' or 'unknown' in the dataset, based on the outcome definitions available at the time data were collected.[19] Time of LFU for each patient was identified by their recorded duration of treatment in months. The treatment cohorts included in this analysis used a variety of drug regimens and treatment lengths, most were 20-24 months. Those with a duration of treatment longer than 24 months (n=800) were truncated at 24 months. Records were excluded if lead investigators did not give consent for their data to be included or if there was no record of duration of treatment. We also excluded patient records whose outcome was death. Although it is possible that some of these patients may have chosen to stop MDR-TB treatment before death, the dataset did not include this detail so we decided to exclude all patients who died.

We identified the independent variables from the dataset to include in the analysis from previous studies where significant associations with LFU had been identified (see introduction). Variables included in the analysis were: age, sex, HIV co-infection status, extensive TB disease (defined as Acid Fast Bacillus (AFB) smear positive, or cavities on chest radiography if no information about AFB-smear was available), type of regimen (standardised v individualised), previous TB therapy (defined as

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

treatment with first-line, or second-line TB drugs for 1 month or more), recorded drug resistance to pyrazinamide, ethambutol and streptomycin, recorded serious adverse events and AFB-smear status. We were also interested in variations by national income and so we distinguished study cohorts from high-income and middle-income countries within the analysis (according to World Bank classifications).[20] There were no cohorts from low-income countries.

The proportion of all patients who were LFU are reported. As the data were negatively skewed we used quantile regression analysis to compare median time to LFU for subgroups (per independent variable). We then employed Kaplan-Meier methods to plot survival curves and estimate the unadjusted time to LFU across the treatment period. To explore this distribution further, we undertook sensitivity analysis by plotting timing of LFU by each cohort within the data set, comparing middle-income and high-income countries and by removing one large cohort. Lastly, a Cox proportional hazards model was created to assess the effects of potential risk factors on LFU, using adjusted hazard ratios with 95% confidence intervals and the associated (two-sided) p-values. Patient-level data were considered to be clustered within study cohorts and so the model used a random-effects, multi-level analysis to account for this. SAS software (SAS Institute Inc. version 9.4) was used to undertake the statistical analysis. The original ethics approval for the analysis of anonymised data for the *Collaborative Group for Meta-Analysis of Individual Patient Data*[1] covered also this secondary analysis and therefore no separate ethics review was needed.

**Results**

Data originated from 23 countries: ten studies were from Asia (four of which were from South Korea), six from North America, five from Europe, four from Central and South America, four from former Soviet states, two from South Africa and one from Iran. The exclusions from the full dataset (n=9,153) were one treatment cohort without permission to include (n=607), patients with no follow-up time recorded (n=1,333) or with an outcome of death (n=1,243). Our dataset therefore included

1  
2  
3 144 5,970 patients, of which 1,282 (21.5%) were recorded as LFU. This LFU rate is  
4 145 comparable with that reported in the full data set (23%).[1] The characteristics of the  
5 146 patients in our dataset are described in table 1.

6  
7  
8 147

9  
10 148

11 149 Table 1 – Characteristics of MDR-TB patients and the median time to loss-to-follow-  
12 150 up

13  
14 151 Insert Table 1 here

15 152 MDR-TB: multidrug-resistant tuberculosis; LFU: lost to follow-up; IQR: inter-quartile range; HIV: human immunodeficiency virus;  
16 153 AFB: acid-fast bacillus test

17  
18 154

19  
20 155 After six months of treatment, 26% (n=336) of those who were recorded as LFU had  
21 156 been lost (Fig. 1). At the end of the intensive stage of treatment at 8 months 35%  
22 157 (n=448) had been lost. By the 12 month stage 44% (n=567) had been lost and by 18  
23 158 months it was 88% (n=1124).

24  
25 159 Figure 1 – Cumulative percentage of LFU\* for all MDR-TB patients and for LFU  
26 160 patients by month of treatment

27 161 Insert Fig.1 here

28 162 Note: The two sets of data points show the timing of LFU among all MDR-TB patients (n=5,970) and for those that were  
29 163 recorded as LFU (n=1,243). \*LFU: loss to follow up

30  
31 164

32 165 For all patients recorded as LFU, the median time to LFU was 16 months (inter-  
33 166 quartile range (IQR) 6-18 months). The median time to LFU was much lower in some  
34 167 sub-groups (Table 1): for example, those over 50 years old (median time to LFU 9  
35 168 months (IQR 5-18), high-income country cohorts (8 months; IQR 5-16), negative HIV  
36 169 status (11 months; IQR 5-18), individualised treatment regime (7 months; IQR 3-14),  
37 170 no previous TB treatment (10 months, IQR 6-18) and previous MDR-TB treatment  
38 171 (12 months; IQR 5-18). Time to LFU also varied by the decade in which cohorts were  
39 172 treated and the median time was much longer in patients starting treatment in the  
40 173 latter decade.

41  
42 174

43 175 **Timing of LFU**

44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For all patients recorded as LFU, the rate of LFU occurrence is steady in the first 17 months of treatment (Fig. 2). A substantial change in probability of being LFU then occurs around month 18 of treatment. We suspected this may have been artefactual and therefore conducted further analysis (see supplementary material and Fig. 3). From this we identified a large cohort from South Africa (n=1,789) which appeared to contribute to this change in probability at 18 months. After removing this large cohort, the plot of time to LFU in the reduced data set indicates it was indeed responsible (Fig. 4).

Figure 2 - Time to Loss-to-Follow-Up after starting MDR-TB treatment for all patients, using Kaplan-Meier analysis  
Insert Fig. 2 here

Figure 3 – Time to Loss-to-Follow-Up after starting MDR-TB treatment, for patients by national income category, using Kaplan-Meier analysis  
Insert Fig. 3 here

Figure 4 - Time to Loss-to-Follow-Up after starting MDR-TB treatment for all patients (minus a large South African cohort), using Kaplan-Meier analysis (n=4,181)  
Insert Fig. 4 here

**Risk factors associated with loss-to-follow-up**

After adjusting for all other variables in a Cox proportional hazards model, several risk factors were significantly associated with LFU (Table 2 and Figure 5). Those aged 26-35 and 36-50 years old had 20% and 28% higher incidence of LFU respectively (HR 1.20; 95% CI 1.04, 1.39 and HR 1.28; 95% CI 1.09, 1.49 respectively) compared to those aged 0-25 years old. Males had a 13% higher incidence of LFU (HR 1.13; 95% CI 1.04, 1.23) compared to females. Those with HIV had a 36% higher incidence of LFU (HR 1.36; 95% CI 1.02, 1.80) compared to HIV negative patients. Those receiving an individualised treatment regimen had 45% lower incidence of LFU (HR 0.55; 95% CI 0.32, 0.93) compared with a standardised regimen.

208

209

210 Table 2 – Risk factors associated with loss-to-follow-up among all MDR-TB patients  
211 (n=5,970)

212 Insert Table 2 here

213 MDR-TB: multidrug-resistant tuberculosis; CI: confidence interval; HIV: human immunodeficiency virus; AFB: acid-fast bacillus  
214 test; HIC: high-income country; MIC: middle-income country

215

216 Figure 5 – Adjusted hazard ratios of risk factors associated with loss-to-follow-up  
217 among all MDR-TB patients (n=5,970)

218 Insert Fig. 5 here

219

220

221

## 222 Discussion

223 Incomplete treatment of MDR-TB is an important driver of continued transmission  
224 and avoidable TB morbidity and mortality worldwide. Using the largest dataset of  
225 individual MDR-TB patients currently available, our study is the most comprehensive  
226 assessment to date of the timing and risk factors for LFU. The overall frequency of  
227 21.5% is similar to that reported by WHO from global TB monitoring[4]. The median  
228 time to LFU was 16 months (IQR 6-18 months). Sub-groups with a higher risk of LFU  
229 were 26-50 year olds, males, those with HIV+ status and those receiving a  
230 standardised treatment regimen.

231 The timing of LFU for patients in our study is predominantly in the continuation phase  
232 of treatment (months 8–24) with a large change in LFU at 18 months. Further  
233 analysis identified that a large cohort from South Africa (n=1,789) was mainly  
234 responsible for this change, which is likely to be artefactual in nature. The reporting  
235 practices of the TB programme at the time caused many patients to be assigned  
236 LFU at 18 months, even though they may have met the criteria for LFU well before  
237 this date (personal communication with study authors)..

238 The timing of LFU in our study differs markedly from studies reporting more recent  
239 treatment cohorts, where the majority of LFU tended to be in the initial intensive  
240 phase of treatment (see Introduction). The treatment of all patients in our study

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

predates 2008, compared with these LFU studies of MDR-TB patients which tend to be more recent (published 2006 – 2015)[7-16]. It is possible that the distribution of timing of LFU has changed over time. Further research on aggregated data from more recent cohorts would help to identify if a different pattern exists for timing of LFU compared with our older cohorts in this study.

Some of the patient-related risk factors associated with LFU which we identify are similar to those found in previous studies. Being male is a common risk factor for poor adherence in many health conditions[22] and has been identified in MDR-TB patients previously[6]. As the majority of MDR-TB patients receiving treatment globally are male[4] this is an important driver of rates of LFU. This association with sex is complex[23]. It is difficult to separate individual behaviours and responses to treatment by males compared to females, from structural factors such as the social construct of gender identities and the delivery of health care services[24]. For example, the opening times of TB treatment centres can be incompatible with regular access from workers in labour markets structured differentially by gender[25]. Being male may also be associated with attitudes and behaviours shaped by cultural factors which predispose to interruption (e.g. itinerancy, alcohol use)[24]. Further qualitative research with MDR-TB patients (particularly men who do not complete treatment, although they can be difficult to access) could shed light on this complex area of treatment adherence.

Having co-infection of HIV is a risk factor for LFU in our analysis with MDR-TB patients. Historically, poor access to anti-retroviral treatment and the lack of co-ordination between HIV and TB treatment programmes have been highlighted as factors which lead to worse outcomes for those co-infected[26]. In addition, these patients might develop some other infectious or non-infectious complication, which precludes continuation of their MDR-TB treatment. Our analysis underlines the importance of identifying and addressing the particular challenges faced by patients who are co-infected with HIV, to improve their chance of a successful treatment outcome.

Better treatment outcomes in children compared with adults have been reported in co-infected HIV populations[27] and non-HIV populations[28]. An increased risk of LFU in those aged 26-50 was identified in our analysis. This could be explained by increased family support offered to younger and older family members with MDR-TB.

274 Furthermore, the competing demands of employment and dependents for individuals  
275 in the working age groups could also be influential in their greater risk of LFU[25].

276 For several variables in our Cox proportional hazards model, the 'unknown' category  
277 was significantly associated with being LFU (resistance to pyrazinamide, resistance  
278 to streptomycin and serious adverse events). Weaker TB treatment programmes  
279 may be the confounding factor, where poorer recording practices and limited efforts  
280 at following up patients are both associated with weaker programmes.

281 The study has several imitations. The large number (35%) of excluded patient  
282 records, largely as a result of missing data of time to LFU or death, may have  
283 introduced bias in our findings. The data quality was variable, although attempts  
284 have been made to ensure the dataset is as complete as possible. There are likely to  
285 be other artefactual influences on our data set beyond those we identified from the  
286 large South African cohort, which are unaccounted for in our analysis. This dataset is  
287 largely restricted to patients who had received one month or more of treatment. This  
288 could have led to an artefactual prolongation of LFU as patients who would have  
289 been early interrupters were selectively removed from the cohorts. We did not have  
290 data available for some patient variables that we were interested in, such as co-  
291 morbid substance misuse or treatment interruptions of less than two consecutive  
292 months. Furthermore, there are likely to be other types of programme-related or  
293 treatment-related risk factors that are associated with LFU which we did not analyse  
294 and which could explain LFU more fully. All datasets pre-date 2008 so these findings  
295 may not generalise to current programme management of MDR-TB. For instance the  
296 use of a standardised 9-11 month regimen recommended by WHO since 2016 in  
297 selected MDR-TB patients has the potential to reduce LFU due to a substantially  
298 shorter duration of treatment than previous MDR-TB regimens.[29]

299 Although some treatment cohorts in this dataset were from resource-constrained  
300 contexts, none were from low-income countries. Our findings therefore may not  
301 generalise to these settings. We have identified risk factors that are associated with  
302 LFU - further work needs to be done to explore the mechanisms that drive stubbornly  
303 high rates of LFU in all MDR-TB programmes including in low-income settings. For  
304 instance, the presence of co-morbid depression may reduce adherence in MDR-TB  
305 as it does in other health conditions. [22, 30]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Our study identifies risk factors associated with being LFU which can guide policy makers to target interventions at those most at risk, such as men of working age. Treatment programmes should consider how best to maintain engagement with these men in an approach that is person-centred and accessible at times and in locations that are convenient for them. In addition, patients with a co-morbid HIV infection are more at risk of being LFU. The policy rhetoric that highlights the need for co-ordination of treatment between both diseases must be implemented by TB and HIV treatment programmes.

**Conclusion**

The call within the global End TB strategy of patient-centred care should be pursued to address the ongoing issue of LFU. Our findings suggest that MDR-TB treatment programmes could offer targeted, enhanced support to prevent LFU in men, those of working age and patients with HIV co-infection. The use of individualised treatment regimens may also be beneficial to combat LFU. Further research examining the timing of LFU in more recent treatment cohorts would add to our knowledge of this important aspect of MDR-TB treatment.

**Acknowledgements**

We would like to thank all the members of the *Collaborative Group for Meta-Analysis of Individual Patient Data* who allowed us to use their data in this study.

Funding for this analysis was provided by COMDIS-HSD, a research consortium funded by UK aid from the UK government: however, the views expressed do not necessarily reflect the UK government's official policies. The funder had no bearing on the study findings nor did they approve or censor the manuscript

DF is a staff member of the World Health Organization (WHO); he alone is responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of WHO. The designations used and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country,

territory, city or area, or of its authorities, nor concerning the delimitation of its  
frontiers or boundaries.

338

## 339 References

- 340 1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A,  
341 Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D,  
342 Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH,  
343 Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane  
344 V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M,  
345 Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A, Riekstina V,  
346 Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J,  
347 Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas  
348 MH, Viiklepp P, Westenhoeuse J, Yew WW, Yim JJ, Collaborative Group for Meta-Analysis of Individual  
349 Patient Data in M-T. Multidrug resistant pulmonary tuberculosis treatment regimens and patient  
350 outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Med* 2012; 9(8):  
351 e1001300.
- 352 2. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, Hollm-Delgado M-G, Keshavjee S,  
353 DeRiemer K, Centis R. Resistance to fluoroquinolones and second-line injectable drugs: impact on  
354 MDR-TB outcomes. *European Respiratory Journal* 2012: erj01347-02012.
- 355 3. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado M-G,  
356 Palmero D, Pérez-Guzmán C, Vargas MH. Drug resistance beyond XDR-TB: results from a large  
357 individual patient data meta-analysis. *European Respiratory Journal* 2012: erj01363-02012.
- 358 4. World Health Organization. Global Tuberculosis Report 2017. Geneva: WHO; 2017.
- 359 5. World Health Organisation. Health in 2015: from MDGs, Millennium Development Goals to  
360 SDGs, Sustainable Development Goals. WHO, Geneva, 2015.
- 361 6. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-  
362 resistant tuberculosis: a systematic review and meta-analysis. *PloS one* 2009; 4(9): e6914.
- 363 7. Cox HS, Kalon S, Allamuratova S, Sizaie V, Tigay ZN, Rüsche-Gerdes S, Karimovich HA, Kebede  
364 Y, Mills C. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan:  
365 treatment complexity and XDR-TB among treatment failures. *PloS one* 2007; 2(11): e1126.
- 366 8. Holtz T, Lancaster J, Laserson K, Wells C, Thorpe L, Weyer K. Risk factors associated with  
367 default from multidrug-resistant tuberculosis treatment, South Africa, 1999–2001. *The International  
368 Journal of Tuberculosis and Lung Disease* 2006; 10(6): 649–655.
- 369 9. Miller A, Gelmanova I, Keshavjee S, Atwood S, Yanova G, Mishustin S, Furin J, Shin S. Alcohol  
370 use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. *The  
371 International Journal of Tuberculosis and Lung Disease* 2012; 16(7): 891–896.
- 372 10. Tupasi TE, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, Balane GI, Basilio  
373 R, Golubkov A, Joson ES, Lew WJ, Lofranco V, Mantala M, Pancho S, Sarol JN, Jr. Factors Associated  
374 with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–  
375 2014. *Emerging infectious diseases* 2016; 22(3).
- 376 11. Kuchukhidze G, Kumar AM, de Colombani P, Khogali M, Nanava U, Blumberg HM, Kempker  
377 RR. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in  
378 Georgia. *Public health action* 2014; 4(Suppl 2): S41–46.
- 379 12. Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z, Khaemraev A, Braker K, Telnov O,  
380 du Cros P. Risk factors associated with default from multi- and extensively drug-resistant  
381 tuberculosis treatment, Uzbekistan: a retrospective cohort analysis. *PloS one* 2013; 8(11): e78364.
- 382 13. Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, Bastard M,  
383 Bonnet M. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a

1  
2  
3 384 quantitative and qualitative study. *The International Journal of Tuberculosis and Lung Disease* 2014:  
4 385 18(2): 160-167.  
5 386 14. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK. Loss-To-Follow-Up on Multidrug Resistant  
6 387 Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It. *PloS one* 2015: 10(7): e0132543.  
7 388 15. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, Weyer K, Lancaster J, Van der  
8 389 Walt M. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African  
9 390 Patients with High HIV Prevalence. *PloS one* 2011: 6(7): e20436.  
10 391 16. Javaid A, Shaheen Z, Shafqat M, Khan AH, Ahmad N. Risk factors for high death and loss-to-  
11 392 follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic  
12 393 management unit. *American journal of infection control* 2017: 45(2): 190-193.  
13 394 17. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in  
14 395 drug-resistant tuberculosis: systematic review and meta-analysis. *Int J Tuberc Lung Dis* 2013: 17(3):  
15 396 299-307.  
16 397 18. Yin J, Yuan J, Hu Y, Wei X. Association between Directly Observed Therapy and Treatment  
17 398 Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. *PloS one*  
18 399 2016: 11(3): e0150511.  
20 400 19. Laserson K, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V, Zarovska E, Rich M, Fraser  
21 401 H, Alarcón E. Speaking the same language: treatment outcome definitions for multidrug-resistant  
22 402 tuberculosis. *The International Journal of Tuberculosis and Lung Disease* 2005: 9(6): 640-645.  
23 403 20. The World Bank. South Asia Region. 2016 [cited; Available from:  
24 404 <http://www.worldbank.org/en/region/sar>  
25 405 21. Institute of Medicine. The New Profile of Drug Resistant Tuberculosis in Russia: A Global and  
26 406 Local Perspective: Summary of a Joint Workshop. The National Academies Press, Washington DC,,  
27 407 2011.  
28 408 22. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of  
29 409 systematic reviews. *Front Pharmacol* 2013: 4: 91.  
30 410 23. Diwan VK, Thorson A. Sex, gender, and tuberculosis. *The Lancet*: 353(9157): 1000-1001.  
31 411 24. Munro SAL, S.A. Smith, H.J. Engel, M.E. Fretheim, A. Volmink, J. Patient Adherence to  
32 412 Tuberculosis Treatment: A Systematic Review of Qualitative Research. *PLoS Med* 2007: 4(7): e238.  
33 413 25. Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, Parmar  
34 414 M, Moonan PK, Lo TQ. Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB  
35 415 Treatment: A Qualitative Study from a Drug Resistant TB Centre in India. *PloS one* 2015: 10(8):  
36 416 e0135802.  
37 417 26. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV  
38 418 infection and multidrug-resistant tuberculosis—the perfect storm. *The Journal of infectious diseases*  
39 419 2007: 196(Supplement\_1): S86-S107.  
40 420 27. Isaakidis P, Casas E, Das M, Tseretopoulou X, Ntzani E, Ford N. Treatment outcomes for HIV  
41 421 and MDR-TB co-infected adults and children: systematic review and meta-analysis. *The International*  
42 422 *Journal of Tuberculosis and Lung Disease* 2015: 19(8): 969-978.  
43 423 28. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with  
44 424 multidrug-resistant tuberculosis: a systematic review and meta-analysis. *The Lancet Infectious*  
45 425 *Diseases*: 12(6): 449-456.  
46 426 29. Khan FA, Salim MH, du Cros P, Casas EC, Khamraev A, Sikhondze W, Benedetti A, Bastos M,  
47 427 Lan Z, Jaramillo E. Effectiveness and safety of standardised shorter regimens for multidrug-resistant  
48 428 tuberculosis: individual patient data and aggregate data meta-analyses. *European Respiratory*  
49 429 *Journal* 2017: 50(1): 1700061.  
50 430 30. Walker IF, Baral SC, Wei X, Huque R, Khan A, Walley J, Newell JN, Elsey H. Multidrug-resistant  
51 431 tuberculosis treatment programmes insufficiently consider comorbid mental disorders. *The*  
52 432 *International Journal of Tuberculosis and Lung Disease* 2017: 21(6): 603-609.  
53  
54  
55 433  
56 434  
57  
58  
59  
60

1  
2  
3 435  
4  
5 436  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60








Figure 1 – Cumulative percentage of LFU\* for all MDR-TB patients and for LFU patients by month of treatment









Characteristic		Number of patients in group (% of total)	Those recorded as LFU (% of total LFU)	Percentage of each category that were LFU	Median time to LFU in months (IQR)
<b>Total</b>	All patients	5,970 (100%)	1,282 (100 %)	21.5%	16 (6-18)
<b>Sex</b>	Female	1,933 (32.4)	384 (30.0)	19.9%	17 (7-18)
	Male	4,037 (67.6)	898 (70.0)	22.2%	15 (6-18)
<b>Age</b>	0-25	1,041 (17.4)	184 (14.4)	17.7%	16 (6-18)
	26-35	1,755 (29.4)	385 (30.0)	21.9%	17 (8-18)
	36-50	2,107 (35.3)	500 (39.0)	23.7%	16 (7-18)
	51-99	1,067 (17.9)	213 (16.6)	20.0%	9 (5-18)
<b>National income category</b>	High-income country	2,266 (38.0)	438 (34.2)	19.3%	8 (5-16)
	Middle-income country	3,704 (62.0)	844 (65.8)	22.8%	18 (8-18)
<b>HIV status</b>	Negative	4,509 (75.5)	881 (68.7)	19.5%	11 (5-18)
	Positive	504 (8.4)	154 (12.0)	30.6%	18 (17-18)
	Unknown	957 (16.0)	247 (19.3)	25.8%	18 (15-18)
<b>Extensive TB disease</b>	No	1,587 (26.6)	317 (24.7)	20.0%	17 (6-18)
	Yes	4,273 (71.6)	939 (73.2)	22.0%	15 (6-18)
	Unknown	110 (1.8)	26 (2.0)	23.6%	18 (17-18)
<b>Treatment regimen</b>	Standardised	2,166 (36.3)	614 (47.9)	28.3%	18 (17-18)
	Individualised	3,804 (63.7)	668 (52.1)	17.6%	7 (3-14)
<b>Previous TB treatment</b>	None	1,132 (19.0)	240 (18.7)	21.2%	10 (6-18)
	First line TB drugs	3,644 (61.0)	806 (62.9)	22.1%	18 (8-18)
	Second line TB drugs	743 (12.4)	144 (11.2)	19.4%	12 (5-18)
	Unknown	451 (7.6)	92 (7.2)	20.4%	10 (4-17)
<b>Resistance to Pyrazinamide</b>	Susceptible	1,202 (20.1)	211 (16.5)	17.6%	10 (6-17)
	Resistant	1,664 (27.9)	289 (22.5)	17.4%	9 (5-16)
	Unknown	3,104 (52.0)	782 (61.0)	25.2%	18 (8-18)
<b>Resistance to Ethambutol</b>	Susceptible	1,604 (26.9)	322 (25.1)	20.1%	8 (4-15)
	Resistant	2,431 (40.7)	429 (33.5)	17.6%	8 (4-16)
	Unknown	1,935 (32.4)	531 (41.4)	27.4%	18 (17-18)
<b>Resistance to Streptomycin</b>	Susceptible	984 (16.5)	204 (15.9)	20.7%	7 (4-12)
	Resistant	2,896 (48.5)	536 (41.8)	18.5%	8 (4-13)
	Unknown	2,090 (35.0)	542 (42.3)	25.9%	18 (18-18)
<b>Serious adverse events</b>	No	2,254 (37.8)	606 (47.3)	26.9%	18 (10-18)
	Yes	1,335 (22.4)	280 (21.8)	21.0%	16 (8-18)
	Unknown	2,381 (39.9)	396 (30.9)	16.6%	8 (4-15)
<b>AFB smear</b>	Negative	1,278 (21.4)	272 (21.2)	21.3%	18 (8-18)
	Positive	3,583 (60.0)	830 (64.7)	23.2%	16 (6-18)
	Unknown	1,109 (18.6)	180 (14.0)	16.2%	10 (6-18)
<b>Years of study for included cohorts</b>	1980+ (4 cohorts)	100 (1.7)	9 (0.7)	9.0%	8 (4-13)
	1990-99 (10 cohorts)	910 (15.2)	234 (18.3)	25.7%	8 (4-12)
	1990-2008 (5 cohorts)	404 (6.8)	56 (4.4)	13.9%	6 (6-8)
	2000-2008 (12 cohorts)	4,556 (76.3)	983 (76.7)	21.6%	18 (8-18)


Variable		Unadjusted Hazard Ratio (95% CI)	p value	Adjusted Hazard Ratio (95% CI)	p value
Sex	Female	reference	-	reference	-
	Male	1.20 (1.03, 1.40)	0.02	1.13 (1.04, 1.23)	<0.01
Age	0-25	reference	-	reference	-
	26-35	1.35 (1.04, 1.74)	0.02	1.20 (1.04, 1.39)	0.01
	36-50	1.47 (1.00, 2.17)	0.05	1.28 (1.09, 1.49)	<0.01
	51-99	1.29 (0.75, 2.22)	0.37	1.20 (0.85, 1.69)	0.30
National income category	HIC	reference	-	reference	-
	MIC	1.33 (0.69, 2.57)	0.40	0.83 (0.51, 1.34)	0.45
HIV status	Negative	reference	-	reference	-
	Positive	1.64 (1.21, 2.22)	<0.01	1.36 (1.02, 1.80)	0.04
	Unknown	1.34 (1.06, 1.70)	0.01	1.18 (0.87, 1.60)	0.29
Extensive TB disease	No	reference	-	reference	-
	Yes	1.07 (0.81, 1.42)	0.65	0.82 (0.56, 1.21)	0.32
	Unknown	1.21 (0.53, 2.75)	0.65	1.03 (0.57, 1.87)	0.92
TB Treatment regimen	Standardised	reference	-	reference	-
	Individualised	0.55 (0.35, 0.85)	<0.01	0.55 (0.32, 0.93)	0.03
Previous TB treatment	None	reference	-	reference	-
	TB	1.08 (0.72, 1.64)	0.71	0.75 (0.55, 1.01)	0.06
	MDR-TB	0.75 (0.33, 1.74)	0.51	0.91 (0.62, 1.35)	0.64
	Unknown	1.24 (0.53, 2.91)	0.62	0.90 (0.46, 1.77)	0.75
Resistance to Pyrazinamide	Susceptible	reference	-	reference	-
	Resistant	0.95 (0.79, 1.14)	0.59	1.02 (0.85, 1.22)	0.87
	Unknown	1.93 (1.38, 2.70)	<0.01	2.86 (2.03, 4.02)	<0.01
Resistance to Ethambutol	Susceptible	reference	-	reference	-
	Resistant	0.77 (0.58, 1.04)	0.09	0.92 (0.77, 1.10)	0.36
	Unknown	1.21 (0.81, 1.82)	0.36	1.08 (0.84, 1.39)	0.56
Resistance to Streptomycin	Susceptible	reference	-	reference	-
	Resistant	1.05 (0.64, 1.71)	0.85	1.14 (0.79, 1.65)	0.49
	Unknown	1.38 (0.73, 2.61)	0.32	0.34 (0.20, 0.57)	<0.01
Serious Adverse Events	No	reference	-	reference	-
	Yes	0.77 (0.44, 1.34)	0.36	0.85 (0.42, 1.71)	0.64
	Unknown	0.48 (0.28, 0.83)	<0.01	0.56 (0.35, 0.89)	0.01
AFB Smear	Negative	reference	-	reference	-
	Positive	1.11 (0.82, 1.51)	0.51	1.31 (0.87, 1.97)	0.20
	Unknown	0.71 (0.40, 1.27)	0.24	1.14 (0.62, 2.09)	0.68

## Analysis of loss to follow up in 5,970 multidrug-resistant pulmonary tuberculosis patients


Ian F. Walker, Oumin Shi, Joseph Hicks, Helen Elsey, Xiaolin Wei, Dick Menzies, Dennis Falzon, Giovanni Battista Migliori, Carlos Pérez-Guzmán, Mario H. Vargas, Lourdes García-García, José Sifuentes Osornio, Alfredo Ponce-De-León, Martie van der Walt and James N. Newell

**Supplementary Data – Kaplan-Meier plots by cohort (Combined sample size N=5,970) Shaded areas are confidence intervals.**


Cohort i – Canada (n=70)




Cohort ii – USA (n=35)




Cohort iii – Taiwan (n=120)




Cohort iv – Mexico (n=35)



Cohort v - South Korea (n=145)




Cohort vi – Hong Kong (n=96)




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Cohort vii - Italy (n=82)




Cohort viii – Peru (n=529)




Cohort ix - Mexico (n=33)




Cohort x – Argentina (n=100)




Cohort xi - UK (n=24)




Cohort xii – Spain (n=21)




Cohort xiii – Vietnam (n=144)




Cohort xiv – Latvia (n=949)




Cohort xv - France (n=30)




Cohort xvi – USA (n=236)




Cohort xvii - Russian Federation (n=577)




Cohort xviii – South Africa (n=33)




Cohort xix – South Korea (n=130)




Cohort xx – Japan (n=59)




Cohort xxi – Philippines (n=146)




Cohort xxii – Iran (n=35)




Cohort xxiii – Estonia (n=253)




Cohort xxiv – South Africa (n=1,789)



Cohort xxv – The Netherlands (n=41)



Cohort xxvi – South Korea (n=191)



Cohort xxvii – Uzbekistan (n=67)

